Beta Bionics [BBNX] vs Novocure [NVCR] Detailed Stock Comparison
Beta Bionics
NASDAQ
Loading...
Novocure
NASDAQ
Loading...
TLDR: Quick Comparison Summary
Based on 18 vital metrics comparison: Beta Bionics wins in 6 metrics, Novocure wins in 11 metrics, with 0 ties. Novocure appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Beta Bionics | Novocure | Better |
|---|---|---|---|
| P/E Ratio (TTM) | -17.42 | -9.40 | Beta Bionics |
| Price-to-Book Ratio | 3.21 | 4.69 | Beta Bionics |
| Debt-to-Equity Ratio | 2.22 | 200.39 | Beta Bionics |
| PEG Ratio | 3.90 | -0.58 | Novocure |
| EV/EBITDA | -11.82 | -8.99 | Beta Bionics |
| Profit Margin (TTM) | -94.04% | -27.13% | Novocure |
| Operating Margin (TTM) | -85.52% | -24.89% | Novocure |
| Return on Equity | 22.32% | -48.07% | Beta Bionics |
| Return on Assets (TTM) | -36.59% | -8.64% | Novocure |
| Free Cash Flow (TTM) | $-51.67M | $-69.22M | Beta Bionics |
| 1-Year Return | -6.51% | -0.41% | Novocure |
| Price-to-Sales Ratio (TTM) | 12.40 | 2.60 | Novocure |
| Enterprise Value | $724.61M | $1.43B | Novocure |
| EV/Revenue Ratio | 9.29 | 2.27 | Novocure |
| Gross Profit Margin (TTM) | 53.80% | 73.88% | Novocure |
| Revenue per Share (TTM) | $4 | $6 | Novocure |
| Earnings per Share (Diluted) | $-1.69 | $-1.56 | Novocure |
| Beta (Stock Volatility) | N/A | 0.75 | N/A |
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends
Beta Bionics vs Novocure Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Beta Bionics | -1.39% | 13.98% | 13.11% | 64.64% | 106.69% | -5.80% |
| Novocure | -1.09% | 13.73% | 21.36% | -17.22% | -13.66% | -51.12% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Beta Bionics | -6.51% | -6.51% | -6.51% | -6.51% | -6.51% | -6.51% |
| Novocure | -0.41% | -81.98% | -89.43% | -30.26% | -19.80% | -19.80% |
News Based Sentiment: Beta Bionics vs Novocure
Beta Bionics
News based Sentiment: POSITIVE
Beta Bionics demonstrated strong Q2 earnings, exceeding expectations, and secured a significant analyst upgrade. While insider selling is a concern, the influx of institutional investment and strategic partnership with Abbott suggest a positive trajectory for the company, making this a noteworthy month for investors.
Novocure
News based Sentiment: MIXED
Novocure showcased strong clinical trial results and continued revenue growth, but remains unprofitable and faces mixed analyst opinions. The upcoming FDA submissions and Q3 earnings report will be critical catalysts for the stock's performance, creating a mixed investment narrative.
Performance & Financial Health Analysis: Beta Bionics vs Novocure
| Metric | BBNX | NVCR |
|---|---|---|
| Market Information | ||
| Market Cap | $1.10B | $1.64B |
| Market Cap Category | Small cap | Small cap |
| 10 Day Avg. Volume | 803,623 | 2,239,560 |
| 90 Day Avg. Volume | 938,151 | 1,734,680 |
| Last Close | $21.95 | $14.50 |
| 52 Week Range | $8.89 - $26.66 | $10.87 - $34.13 |
| % from 52W High | -17.67% | -57.52% |
| All-Time High | $26.66 (Sep 12, 2025) | $232.76 (Jun 21, 2021) |
| % from All-Time High | -17.67% | -93.77% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.54% | 0.06% |
| Quarterly Earnings Growth | 0.80% | 0.06% |
| Financial Health | ||
| Profit Margin (TTM) | -0.94% | -0.27% |
| Operating Margin (TTM) | -0.86% | -0.25% |
| Return on Equity (TTM) | 0.22% | -0.48% |
| Debt to Equity (MRQ) | 2.22 | 200.39 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $6.94 | $3.13 |
| Cash per Share (MRQ) | $5.75 | $8.15 |
| Operating Cash Flow (TTM) | $-57,461,000 | $-44,676,000 |
| Levered Free Cash Flow (TTM) | $-54,756,000 | $5.94M |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | N/A |
Valuation & Enterprise Metrics Analysis: Beta Bionics vs Novocure
| Metric | BBNX | NVCR |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | -17.42 | -9.40 |
| Forward P/E | -12.39 | -9.77 |
| PEG Ratio | 3.90 | -0.58 |
| Price to Sales (TTM) | 12.40 | 2.60 |
| Price to Book (MRQ) | 3.21 | 4.69 |
| Market Capitalization | ||
| Market Capitalization | $1.10B | $1.64B |
| Enterprise Value | $724.61M | $1.43B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 9.29 | 2.27 |
| Enterprise to EBITDA | -11.82 | -8.99 |
| Risk & Other Metrics | ||
| Beta | N/A | 0.75 |
| Book Value per Share (MRQ) | $6.94 | $3.13 |
Financial Statements Comparison: Beta Bionics vs Novocure
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | BBNX | NVCR |
|---|---|---|
| Revenue/Sales | $17.64M | $154.99M |
| Cost of Goods Sold | $8.67M | $38.52M |
| Gross Profit | $8.97M | $116.47M |
| Research & Development | $7.59M | $53.78M |
| Operating Income (EBIT) | $-18.64M | $-37.87M |
| EBITDA | $-5.59M | $-34.54M |
| Pre-Tax Income | $-28.66M | $-30.30M |
| Income Tax | N/A | $4.02M |
| Net Income (Profit) | $-28.66M | $-34.32M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | BBNX | NVCR |
|---|---|---|
| Cash & Equivalents | $42.45M | $127.28M |
| Total Current Assets | $261.92M | $1.09B |
| Total Current Liabilities | $16.49M | $743.31M |
| Long-Term Debt | $5.45M | $137.76M |
| Total Shareholders Equity | $313.75M | $361.96M |
| Retained Earnings | $-325.39M | $-1.19B |
| Property, Plant & Equipment | $13.04M | $145.02M |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | BBNX | NVCR |
|---|---|---|
| Operating Cash Flow | $-24.83M | $-14.80M |
| Capital Expenditures | $-333,000 | $-10.61M |
| Free Cash Flow | $-20.31M | $-46.28M |
| Debt Repayment | N/A | $0 |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | BBNX | NVCR |
|---|---|---|
| Shares Short | 3.88M | 5.89M |
| Short Ratio | 5.52 | 4.33 |
| Short % of Float | 0.10% | 0.08% |
| Average Daily Volume (10 Day) | 803,623 | 2,239,560 |
| Average Daily Volume (90 Day) | 938,151 | 1,734,680 |
| Shares Outstanding | 42.86M | 108.52M |
| Float Shares | 21.42M | 94.06M |
| % Held by Insiders | 0.01% | 0.10% |
| % Held by Institutions | 1.09% | 0.86% |
Dividend Analysis & Yield Comparison: Beta Bionics vs Novocure
| Metric | BBNX | NVCR |
|---|---|---|
| Last 12-Month Dividend | N/A | N/A |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | N/A |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | N/A | N/A |
| Ex-Dividend Date | N/A | N/A |